Artrya (AYA.AX) A$3.41 on ASX 12 Mar 2026: AI diagnostics growth vs valuation

The AYA.AX stock trades at A$3.41 intraday on the ASX on 12 Mar 2026 as investors weigh Artrya Limited’s AI diagnostic traction against stretched valuation. Volume sits around 500142.00 shares with a day range A$3.38–A$3.50. Artrya’s cloud AI tool Salix supports growth headlines, but negative EPS and high price-to-sales metrics keep valuation risk front of mind.

AYA.AX stock price action and market snapshot

Artrya Limited (AYA.AX) opened at A$3.50 and trades near A$3.41 on ASX with market cap A$398,300,000.00. The stock is up 1.34% today with volume 500142.00 vs average volume 582886.00, signifying below-average intraday activity. One clear market fact: the 50-day average A$3.74 sits above the current price while the 200-day average A$2.63 supports a longer-term uptrend.

AYA.AX stock fundamentals and financial metrics

Artrya reports EPS -0.17 and a trailing PE of -20.59, reflecting current losses. Cash per share is 0.61 and book value per share is 0.71, yielding a PB ratio near 4.93. Revenue per share remains tiny at 0.00, pushing price-to-sales to extreme levels. These figures highlight a growth-stage medtech with strong cash buffers but weak current profitability.

AYA.AX stock valuation and risks

Valuation risks are real for AYA.AX given a price-to-sales ratio above 13000.00 and negative margins. Research and development outlays sit at 84.34% of revenue, which drives near-term operating losses. Low debt (debt-to-equity 0.01) reduces solvency risk, yet the stock’s elevated PB and negative free cash flow metrics increase sensitivity to any slowdown in commercial uptake.

AYA.AX stock technicals and trading signals

Technicals show neutral momentum: RSI 53.32, MACD histogram 0.06, and ADX 18.90 indicating no strong trend. Bollinger bands run A$2.92–A$3.50, and CCI sits at 144.78, suggesting short-term overbought conditions. Traders should note the ROIC and ROE are negative, while on-balance volume is negative, pointing to distribution on lower-volume rises.

AYA.AX stock growth outlook and model forecasts

Meyka AI’s forecast model projects a quarterly target A$4.36 and a one-year target A$7.41 for AYA.AX stock. The model implies a 27.86% upside to the quarter target and 117.30% to the one-year target from A$3.41. Forecasts are model-based projections and not guarantees. Growth drivers include Salix adoption, regulatory clearances, and commercial partnerships.

AYA.AX stock catalysts, opportunities and sector context

Key catalysts for Artrya include expanded clinical deployments and payor acceptance of AI diagnostics. The Healthcare sector on ASX trades higher on average PE of 27.84, making Artrya’s negative earnings a key differentiator. Opportunities exist from cross-selling Salix in markets with rising cardiac CT adoption, but execution risk and reimbursement timing remain primary constraints.

Final Thoughts

Artrya Limited (AYA.AX) presents a classic AI-healthcare trade-off: meaningful product-led growth potential versus stretched near-term valuation. At A$3.41 intraday on 12 Mar 2026, the stock carries significant upside in our model, with a quarterly target A$4.36 and a one-year target A$7.41, implying 27.86% and 117.30% upside respectively. Meyka AI rates AYA.AX with a score out of 100: 63.51 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Investors should watch upcoming earnings and adoption milestones. Short-term traders can use RSI and Bollinger signals for entries, while longer-term investors must accept execution risk and rely on improving revenue conversion to justify current multiples. Meyka AI’s model provides scenario targets but forecasts are projections, not guarantees. For live order flow and updates, see the company site and market feeds

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.